COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study
Objective: To evaluate the association between the BNT162b2 (Pfizer-BioNTech<sup>®</sup>) coronavirus disease vaccine and new-onset anterior uveitis. Methods: A retrospective case control study of patients admitted and diagnosed with new-onset acute anterior uveitis, and matched controls...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/2/176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719132438659072 |
|---|---|
| author | Asaf Shemer Amit Toledano Aya Altarescu Biana Dubinsky-Pertzov Assaf Rozenberg Idan Hecht Adi Einan-Lifshitz Eran Pras |
| author_facet | Asaf Shemer Amit Toledano Aya Altarescu Biana Dubinsky-Pertzov Assaf Rozenberg Idan Hecht Adi Einan-Lifshitz Eran Pras |
| author_sort | Asaf Shemer |
| collection | DOAJ |
| description | Objective: To evaluate the association between the BNT162b2 (Pfizer-BioNTech<sup>®</sup>) coronavirus disease vaccine and new-onset anterior uveitis. Methods: A retrospective case control study of patients admitted and diagnosed with new-onset acute anterior uveitis, and matched controls admitted for other reasons (1:3 ratio), was completed. Rates of exposure to the BNT162b2 vaccine were compared between groups, and odds ratios for exposure to the vaccine were calculated. A secondary analysis of the overall number of patients with new-onset anterior uveitis in the six preceding years was conducted. This study was conducted in one academic center in Israel. Results: A total of 16 patients were admitted for acute anterior uveitis during the study period. Of the 16 cases, 11 (69%) received the first dose of the BNT162b2 vaccine prior to presentation and 8 (50%) also received the second dose. This compares to 39 (81.2%) in the control group. The odds ratio for exposure to the vaccine among cases was 0.508 (95% confidence interval 0.141–1.829, <i>p</i> = 0.300). Compared with preceding years, the rate of cases diagnosed with acute anterior uveitis in 2021 was similar to the six preceding years (mean 11.8 ± 3.4 cases). Conclusions: In this case control study and comparison with preceding years, we found no evidence to suggest an association between vaccination with the BNT162b2 (Pfizer-BioNTech<sup>®</sup>) COVID-19 vaccine and new-onset acute anterior uveitis. |
| format | Article |
| id | doaj-art-47a1abfd2ead4dc589417ca8ade7176f |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-47a1abfd2ead4dc589417ca8ade7176f2025-08-20T03:12:12ZengMDPI AGVaccines2076-393X2025-02-0113217610.3390/vaccines13020176COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control StudyAsaf Shemer0Amit Toledano1Aya Altarescu2Biana Dubinsky-Pertzov3Assaf Rozenberg4Idan Hecht5Adi Einan-Lifshitz6Eran Pras7Department of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelDepartment of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, IsraelObjective: To evaluate the association between the BNT162b2 (Pfizer-BioNTech<sup>®</sup>) coronavirus disease vaccine and new-onset anterior uveitis. Methods: A retrospective case control study of patients admitted and diagnosed with new-onset acute anterior uveitis, and matched controls admitted for other reasons (1:3 ratio), was completed. Rates of exposure to the BNT162b2 vaccine were compared between groups, and odds ratios for exposure to the vaccine were calculated. A secondary analysis of the overall number of patients with new-onset anterior uveitis in the six preceding years was conducted. This study was conducted in one academic center in Israel. Results: A total of 16 patients were admitted for acute anterior uveitis during the study period. Of the 16 cases, 11 (69%) received the first dose of the BNT162b2 vaccine prior to presentation and 8 (50%) also received the second dose. This compares to 39 (81.2%) in the control group. The odds ratio for exposure to the vaccine among cases was 0.508 (95% confidence interval 0.141–1.829, <i>p</i> = 0.300). Compared with preceding years, the rate of cases diagnosed with acute anterior uveitis in 2021 was similar to the six preceding years (mean 11.8 ± 3.4 cases). Conclusions: In this case control study and comparison with preceding years, we found no evidence to suggest an association between vaccination with the BNT162b2 (Pfizer-BioNTech<sup>®</sup>) COVID-19 vaccine and new-onset acute anterior uveitis.https://www.mdpi.com/2076-393X/13/2/176COVID-19SARS-CoV-2coronavirusBNT162b2vaccineuveitis |
| spellingShingle | Asaf Shemer Amit Toledano Aya Altarescu Biana Dubinsky-Pertzov Assaf Rozenberg Idan Hecht Adi Einan-Lifshitz Eran Pras COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study Vaccines COVID-19 SARS-CoV-2 coronavirus BNT162b2 vaccine uveitis |
| title | COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study |
| title_full | COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study |
| title_fullStr | COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study |
| title_full_unstemmed | COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study |
| title_short | COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study |
| title_sort | covid 19 vaccination and acute anterior uveitis a case control study |
| topic | COVID-19 SARS-CoV-2 coronavirus BNT162b2 vaccine uveitis |
| url | https://www.mdpi.com/2076-393X/13/2/176 |
| work_keys_str_mv | AT asafshemer covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT amittoledano covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT ayaaltarescu covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT bianadubinskypertzov covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT assafrozenberg covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT idanhecht covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT adieinanlifshitz covid19vaccinationandacuteanterioruveitisacasecontrolstudy AT eranpras covid19vaccinationandacuteanterioruveitisacasecontrolstudy |